Combining anti-IgE with oral immunotherapy.

Area of Science:

• Clinical Immunology
• Allergy and Immunology
• Pharmacology

Background:

• Food allergy affects up to 8% of children, with current management relying on avoidance and emergency treatment.
• Oral immunotherapy (OIT) shows promise for desensitization but has high reaction rates and variable protection duration.
• Recurrence of sensitivity after OIT discontinuation is a significant challenge.

Purpose of the Study:

• To review the literature on using omalizumab as an adjuvant therapy with OIT for food allergies.
• To evaluate how omalizumab impacts the safety and efficacy of OIT.
• To address remaining questions regarding omalizumab's role in OIT.

Main Methods:

• Review of current scientific literature on clinical trials involving omalizumab and OIT.
• Analysis of data regarding reaction rates, severity, and allergen tolerance thresholds.
• Synthesis of findings to assess the benefits and limitations of the combined approach.

Main Results:

• Omalizumab significantly decreases the frequency and severity of allergic reactions during OIT.
• Co-administration of omalizumab allows for a higher threshold of tolerance to food allergens.
• This adjuvant therapy improves the overall safety and tolerability of OIT.

Conclusions:

• Omalizumab is an effective adjuvant to OIT, enhancing treatment safety and efficacy in food allergy.
• The combination therapy offers a promising strategy to overcome OIT's limitations.
• Further research is needed to address outstanding questions on optimal use.